Internet-based Exposure-based Therapy for Fibromyalgia: A Randomized Controlled Trial.
연구 개요
상세 설명
Trial Objectives: Primary objective is to investigate whether an Internet-based exposure therapy can effectively reduce the degree of Fibromyalgia symptoms and impact. Secondary objectives are to 1) investigate the treatment's ability to reduce degree of a) quality of life b) function c) insomnia and fatigue d) pain-related fear and negative thoughts e) depression and anxiety, cost-effectiveness of this treatment; and 2) to study if any variables could moderate/mediate the treatment outcome, such as a) degree of covert avoidance, b) degree of reactivity to inner sensations
Trial Design: Randomized controlled trial with waitlist control, who also will receive treatment after the first group has finished.
Duration: Ten weeks
Primary Endpoint: Change in Fibromyalgia symptoms and impact from baseline to Week 10. Long term follow-up is also investigated (potential changes from post-treatment to 6- and 12 months after treatment completion)
Efficacy Parameters: the Fibromyalgia Impact Questionnaire (FIQ)
Description of Trial Subjects: Patients > 18 years old, Fibromyalgia diagnosis, residing in Sweden.
Number of Subjects: 140
Sample size estimation: Sample size is based on a estimated effect size (measured by Cohen's d) of 0.5, based on a power of 0.8 and with room for a 10 % dropout rate.
Recruitment: Self-referral. Advertising will be made through national newspaper, social media and on patient organisations' websites.
Safety parameters: Participants will have the opportunity to report any adverse events during treatment at posttreatment and follow-up measurements.
Data collection: Data will be collected electronically via the treatment platform.
Plan for missing data: Last-observation carried forward (LOCF).
Main statistical analysis: Hierarchical linear mixed modelling.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Stockholm
-
Solna, Stockholm, 스웨덴, 17177
- Karolinska Institutet
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Fibromyalgia diagnosis
- Swedish resident
- Internet connection before, under and after treatment
- Willing to refrain from other concurrent psychological treatment during the study
- Agreement to keep psychotrophic medication constant during the study
Exclusion Criteria:
- Severe depression (≥30 points on Montgomery Åsberg Depression Rating Scale - Self Rated (MADRS-S) or risk of suicide (≥4 points on the suicide item on MADRS-S)
- Ongoing alcohol or substance abuse
- Psychosis
- Other severe illness that require immediate treatment and/or was considered the participants primary concern other than FM, or bodily condition that makes treatment unfeasible (such as late pregnancy; >29 weeks gestation
- Illiteracy or poor skills in Swedish language
- Insufficient computer or language skills to manage a text-based treatment.
- Other concurrent psychological treatment
- Recent changes in psychotrophic medication (<6 weeks prior to randomization)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Internet-based exposure therapy
The experimental group will go through active internet-based treatment which is delivered on a safe internet platform.
Treatment is divided into eight modules, each containing homework assignments.
Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
|
The treatment is a 10 week long cognitive behavior therapy.
It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
|
|
간섭 없음: Waitlist
Waitlist control, i.e. no active active intervention during waiting list period.
Will be offered treatment when the first group has finished (i.e.
week 10).
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in the Fibromyalgia Impact Questionnaire (FIQ)
기간: Week 0, week 10, Long term follow-up at 6- and 12-months after treatment has ended]
|
Change in Fibromyalgia symptoms and impact from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, Long term follow-up at 6- and 12-months after treatment has ended]
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Insomnia Severity Index (ISI)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in sleep disturbances from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Fatigue Severity Scale (FSS)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in fatigue from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
WHO Disability Assessment Schedule 2.0 (WHODAS 2)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in level of function from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Brunnsviken Brief Quality of Life Inventory (BBQ)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in quality of life from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
The Psychological Inflexibility in Pain Scale (PIPS)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in covert avoidance from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Pain Reactivity Scale (PRS)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in pain-related fear and negative thoughts from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Patient Health Questionnaire-9 (PHQ-9)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in level of depression from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Generalised Anxiety Disorder 7-item scale (GAD-7)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in level of anxiety from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Subscale "reactivity to inner experiences" from Five Facets of Mindfulness Questionnaire (FFMQ)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in reactivity to inner experiences from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P)
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in health-care costs and sick-leave from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
EQ5D
기간: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in health-related quality of life from baseline to week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Item 9 from Montgomery Asberg Depression Rating Scale (MADRS-S)
기간: Week 1, week 2, week 3, week 4, week 5, week 6, week, 7, week 8, week 9
|
Possible presence of suicidal thoughts or ideation during treatment
|
Week 1, week 2, week 3, week 4, week 5, week 6, week, 7, week 8, week 9
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .